Catalog No.
DHD16101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
PDGFR2, Platelet-derived growth factor receptor alpha, RHEPDGFRA, Alpha platelet-derived growth factor receptor, PDGFR-2, Platelet-derived growth factor alpha receptor, Platelet-derived growth factor receptor 2, PDGF-R-alpha, Alpha-type platelet-derived growth factor receptor, CD140a antigen, CD140 antigen-like family member A, PDGFRA, PDGFR-alpha, CD140a
Concentration
3.22 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16234
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
3G3, IMC-3G3, LY3012207, CAS: 1024603-93-7
Clone ID
Olaratumab
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial, PMID: 32259228
Olaratumab, PMID: 31644245
Olaratumab in soft tissue sarcoma - Current status and future perspectives, PMID: 29413687
Olaratumab, PMID: 29999955
Olaratumab in the management of advanced soft tissue sarcoma, PMID: 30032714
Olaratumab: First Global Approval, PMID: 27995580
Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma, PMID: 30588358
Olaratumab for the treatment of soft-tissue sarcoma, PMID: 28745071
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial, PMID: 27291997
Olaratumab for advanced soft tissue sarcoma, PMID: 28447475
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal, PMID: 28914440
Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma, PMID: 28778132
Olaratumab for the treatment of advanced soft tissue sarcoma, PMID: 28862476
Developments in the management of advanced soft-tissue sarcoma - olaratumab in context, PMID: 29497315
Olaratumab for soft tissue sarcoma, PMID: 28691538
Olaratumab for the treatment of soft tissue sarcoma, PMID: 28492292
Olaratumab for STS Disappoints in Phase III, PMID: 30696623
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma, PMID: 29270033
Incidence and Management of Olaratumab Infusion-Related Reactions, PMID: 31268811
Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria, PMID: 31620878
Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience, PMID: 31996176
Olaratumab failure in sarcomas: what are the lessons learned?, PMID: 31254941
Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy, PMID: 29263653
Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer, PMID: 28620891
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas, PMID: 28917265
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors, PMID: 33474828
Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma, PMID: 30353601
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma, PMID: 30406840
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland, PMID: 32391141
Olaratumab (Lartruvo): An Innovative Treatment for Soft Tissue Sarcoma, PMID: 29719366
Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?, PMID: 31321082
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma, PMID: 31821732
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC, PMID: 28838379
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma, PMID: 33177152
Uterine leiomyosarcoma: A review of the literature and update on management options, PMID: 30244960
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas, PMID: 32235164
Olaratumab's failure in soft tissue sarcoma, PMID: 34349891
Olaratumab in soft-tissue sarcomas, PMID: 27291995
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α, PMID: 29191969
Phase I study of olaratumab in Japanese patients with advanced solid tumors, PMID: 24816152
First-Line Therapy for Metastatic Soft Tissue Sarcoma, PMID: 30675651
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer, PMID: 30573277
Minimization of olaratumab drug waste using real-world data, PMID: 28461327
Olaratumab (Lartruvo) for soft-tissue sarcoma, PMID: 28787747
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab, PMID: 33147355
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer, PMID: 30591028
Drug Monographs: Olaratumab and Rucaparib, PMID: 28515503
Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?, PMID: 32161464
Advances of systemic treatment for adult soft-tissue sarcoma, PMID: 30173532
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation, PMID: 28209496
For research use only. Not for human or drug use.
